News

New Tool Available for Calculating GIST Recurrence

updated 6/22/20 The GIST Risk Calculator is based on research from Dr. Heikki Joensuu, Professor of Oncology at the University of Helsinki and the Research Director at the Helsinki Comprehensive Cancer Center, and his colleagues. The [...]

By |2020-06-22T09:17:59-04:00September 15th, 2016|News, Risk Assessment|

LOXO-101 receives breakthrough therapy designation from FDA for solid tumors with NTRK gene fusions

Loxo Oncology  announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of unresectable or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusions. This [...]

By |2020-02-21T14:56:38-05:00July 21st, 2016|News, Research|

Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well

In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]

By |2018-10-30T09:41:06-04:00July 19th, 2016|Clinical Trials, News, Research|
Go to Top